Propranolol labels and packages: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Propranolol}} | {{Propranolol}} | ||
{{CMG | {{CMG}} | ||
==Labels and Packages== | ==Labels and Packages== | ||
| Line 7: | Line 7: | ||
{| | {| | ||
|[[File:Inderal 60mg.JPG|600px|thumb]] | |[[File:Inderal 60mg.JPG|600px|thumb]] | ||
|} | |} | ||
{| | {| | ||
|[[File:Inderal 80mg.JPG|600px|thumb]] | |[[File:Inderal 80mg.JPG|600px|thumb]] | ||
|} | |} | ||
| Line 21: | Line 19: | ||
{| | {| | ||
|[[File:Inderal 160 mg.JPG|600px|thumb]] | |[[File:Inderal 160 mg.JPG|600px|thumb]] | ||
|} | |||
| | |||
{{FDA}} | {{FDA}} | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Beta blockers]] | |||
Revision as of 22:21, 9 February 2014
| Propranolol |
|---|
| Inderal LA® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Propranolol |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Labels and Packages
 |
 |
 |
 |
Adapted from the FDA Package Insert.